Livedoid vasculitis - Livedoid Vaskulit
Livedoid Vaskulit (Livedoid vasculitis) se yon maladi kwonik ki parèt sitou nan jèn fanm ak fanm ki gen laj mwayen. Yon akwonim yo itilize pou dekri karakteristik li yo se "Ilsè purpurik douloure ak modèl retikul nan ekstremite ki pi ba yo" (PURPLE). Li asosye ak yon kantite maladi, ki gen ladan tansyon wo venn kwonik ak varikozite.
☆ Nan rezilta Stiftung Warentest 2022 ki soti nan Almay, satisfaksyon konsomatè yo ak ModelDerm te sèlman yon ti kras pi ba pase ak konsiltasyon telemedsin peye.
Li ka akonpaye pa doulè.
References
Livedoid vasculopathy se yon maladi po ki ra ki karakterize pa maladi ilsè ki fè lapenn ki kontinye ap tounen sou pye pi ba yo.
Livedoid vasculopathy (LV) is a rare thrombotic vasculopathy of the dermis characterized by painful, relapsing ulcers over the lower extremities. Diagnosis is challenging due to the overlap in clinical appearance and nomenclature with other skin disorders. Treatment selection is complicated by poor understanding of the pathogenesis of LV and lack of robust clinical trials evaluating therapy efficacy. The terminology and pathophysiology of LV are reviewed here, along with its epidemiology, clinical and histologic features, and treatment options. A diagnostic pathway is suggested to guide providers in evaluating for comorbidities, referring to appropriate specialists, and choosing from the available classes of therapy.
Livedoid vasculopathy (LV) is a rare thrombotic vasculopathy of the dermis characterized by painful, relapsing ulcers over the lower extremities. Diagnosis is challenging due to the overlap in clinical appearance and nomenclature with other skin disorders. Treatment selection is complicated by poor understanding of the pathogenesis of LV and lack of robust clinical trials evaluating therapy efficacy. The terminology and pathophysiology of LV are reviewed here, along with its epidemiology, clinical and histologic features, and treatment options. A diagnostic pathway is suggested to guide providers in evaluating for comorbidities, referring to appropriate specialists, and choosing from the available classes of therapy.
Livedoid vasculopathy se yon maladi po ki ra ki lakòz maladi ilsè renouvlab sou pye pi ba yo, kite dèyè mak pal ke yo rekonèt kòm atrophie blanche. Pandan ke kòz egzak la toujou klè, yo kwè ke ogmante kayo san (hypercoagulability) se faktè prensipal la, ak enflamasyon jwe yon wòl segondè. Faktè ki kontribye nan kayo gen ladan jan sa a - deficiencies in proteins C and S, genetic mutations like factor V Leiden, antithrombin III deficiency, prothrombin gene mutations, high levels of homocysteine. Nan byopsi, kondisyon an montre boul nan san andedan veso yo, epesman mi veso yo, ak sikatris. Tretman enplike nan yon apwòch milti-pwen konsantre sou anpeche boul nan san ak medikaman tankou dwòg anti-plakèt, diluant san, ak terapi fibrinolitik. Yo ka itilize plizyè medikaman pou kondisyon po sa a - colchicine and hydroxychloroquine, vasodilators, immunosuppressants.
Livedoid vasculopathy is a rare skin condition that causes recurring ulcers on the lower legs, leaving behind pale scars known as atrophie blanche. While the exact cause is still unclear, it's believed that increased blood clotting (hypercoagulability) is the main factor, with inflammation playing a secondary role. Factors contributing to clotting include as follows - deficiencies in proteins C and S, genetic mutations like factor V Leiden, antithrombin III deficiency, prothrombin gene mutations, high levels of homocysteine. In biopsies, the condition shows blood clots inside vessels, thickening of vessel walls, and scarring. Treatment involves a multi-pronged approach focusing on preventing blood clots with medications like anti-platelet drugs, blood thinners, and fibrinolytic therapy. Various drugs can be used for this skin condition - colchicine and hydroxychloroquine, vasodilators, immunosuppressants.
Livedoid vasculopathy is a rare skin condition that causes recurring ulcers on the lower legs, leaving behind pale scars known as atrophie blanche. While the exact cause is still unclear, it's believed that increased blood clotting (hypercoagulability) is the main factor, with inflammation playing a secondary role. Factors contributing to clotting include as follows - deficiencies in proteins C and S, genetic mutations like factor V Leiden, antithrombin III deficiency, prothrombin gene mutations, high levels of homocysteine. In biopsies, the condition shows blood clots inside vessels, thickening of vessel walls, and scarring. Treatment involves a multi-pronged approach focusing on preventing blood clots with medications like anti-platelet drugs, blood thinners, and fibrinolytic therapy. Various drugs can be used for this skin condition - colchicine and hydroxychloroquine, vasodilators, immunosuppressants.
Livedoid vasculopathy se yon kondisyon ki ra kote blesi yo rive sou tou de janm yo. Yo panse fòmasyon nan boul nan san nan ti veso sangen yo te koze pa ogmante kayo ak diminye pann boul, ansanm ak domaj nan pawa veso a. Li pi komen nan fi, espesyalman ant laj 15 ak 50. Kite fimen, pran swen blesi, ak itilize medikaman tankou diluant san ak dwòg antiplakèt yo te efikas.
Livedoid vasculopathy is a rare vasculopathy that is typically characterized by bilateral lower limb lesions. Increased thrombotic activity and decreased fibrinolytic activity along with endothelial damage are believed to be the cause of thrombus formation in the capillary vasculature. It is 3 times more common in females than in males, especially in patients between the ages of 15 to 50 years. There is no definite first-line treatment, but general measures like smoking cessation, wound care, and pharmacological measures like anticoagulants and antiplatelets have shown good results.
Livedoid vasculopathy is a rare vasculopathy that is typically characterized by bilateral lower limb lesions. Increased thrombotic activity and decreased fibrinolytic activity along with endothelial damage are believed to be the cause of thrombus formation in the capillary vasculature. It is 3 times more common in females than in males, especially in patients between the ages of 15 to 50 years. There is no definite first-line treatment, but general measures like smoking cessation, wound care, and pharmacological measures like anticoagulants and antiplatelets have shown good results.
